Please login to the form below
cell therapies
This page shows the latest cell therapies news and features for those working in and with pharma, biotech and healthcare.
Vertex to lead development of CRISPR Therapeutics-partnered gene therapy
Cell and genetic therapies are key to our strategy of developing transformative therapies for serious diseases, and this agreement is an important next step in cementing our leadership in these modalities ... as we bring forward our broad gene and
Latest news
-
BMS and bluebird bio gain FDA approval for multiple myeloma therapy
Abecma is a CAR T cell therapy approved for pre-treated myeloma patients. ... Samit Hirawat, chief medical officer, BMS said: “CAR T cell therapies have shown transformational potential for the treatment of haematologic malignancies and we, with our
-
Vertex gains FDA fast track designation for diabetes stem cell therapy
Vertex says VX-880 has potential to restore pancreatic islet cell function, including insulin production, in type 1 diabetes patients. ... the team at Vertex,” said Bastiano Sanna, executive vice president and chief of cell and genetic therapies at
-
bluebird bio posts modest Q4 revenue growth as it continues investigation into troubled LentiGlobin
bluebird bio has posted a modest increase in its Q4 revenues and has also provided an update about its clinical hold on its sickle cell disease gene therapy LentiGlobin. ... BMS) and monetisation for ex-US milestones and royalties from CAR T cell
-
Lilly partners with Merus on development of bispecific antibodies for cancer
three CD3-engaging T-cell re-directing bispecific antibody therapies. ... Merus has built a differentiated platform, one that we believe can enable us to create bispecific antibody therapies with wider therapeutic indexes than those available today.
-
Takeda and KSQ Therapeutics to develop immune-based cancer treatments
Takeda will also work with KSQ on the discovery and development of natural killer (NK) cell targeted therapies identified through the collaboration. ... Working alongside KSQ will facilitate smart drug discovery and development of what we hope will be
More from news
Approximately 2 fully matching, plus 143 partially matching documents found.
Latest Intelligence
-
Rare genetic diseases – what’s in store for 2021?
In my opinion, these new pathways will establish themselves and be extended to other treatments, including cell and gene therapies. ... Mike Fraser is General Manager, EMEA at Novartis Gene Therapies. 16th February 2021. .
-
Keeping up with the developing regulatory requirements for gene and cell therapies
By Clive Glover. Since the approval of the first five gene or gene-modified cell therapies in the US – Luxturna, Yescarta, Tecartus, Kymriah and Zolgensma – this new technology has been evolving ... must create manufacturing processes for cell and
-
Sourcing R&D innovation: why pharma companies need to evolve their business models
the first generation of gene and cell therapies. ... Many drug developers also have looked to engage and acquire companies with synergistic discovery-stage platforms to expand their portfolios to include next-generation and potentially curative therapies
-
Successful product commercialisation: what can we learn from the rare disease setting?
This trend is not surprising – in part driven by the pressures facing healthcare budgets through the rising incidence of chronic diseases, as well as the advent of cell and gene therapies ... For novel therapies (including medicines aimed at rare
-
After years of potential, cell and gene therapy is ready for the pharmaceutical mainstream
Thanks to advances in technology and new commercial viability, cell and gene therapy is finally coming of age. ... Another example is Maxcyte, a global cell- based therapies and life sciences company that is developing its CARMA process, where a
More from intelligence
Approximately 0 fully matching, plus 47 partially matching documents found.
Latest appointments
-
Health comms agency emotive hires new cell and gene therapy leader
An expert in cell and gene therapies, Dr Ferrari joins emotive following 20 years in research as well as holding medical affairs and commercial roles in biopharma and diagnostics. ... It is also charged with developing HCP engagement on gene silencing
-
Marinomed appoints CFO, Robin Brown is named chair of Medicines Discovery Catapult and more
Ceylad appoints new CFO. Clinical-stage biopharma focused on the development of CAR-T cell therapies has announced that Filippo Petti has been appointed as Chief Financial Officer. ... He said: “Celyad’s differentiated approach to the field of CAR-T
-
Industry appointments
Rogerio Vivaldi leaves Bioverativ buyout to head up Sigilon. US-based biotech Sigilon aiming to deliver stem cell therapies for diabetes is getting a new leader. ... In the longer term, Hassan will lead research activities with the aim to expand
-
Abeona Therapeutics appoints new additions to board of directors
Stefano Buono and Richard Van Duyne join the biopharma. Abeona Therapeutics, a clinical stage biopharmaceutical company focused on developing cell and gene therapies, has expanded its board of directors through the ... He said: “Abeona’s ambitious
-
Turnstone Biologics bolsters leadership team
Prior to his new role, he was chief business officer at SQZ Biotech, a clinical-stage group focusing on developing cell therapies.
More from appointments
Approximately 0 fully matching, plus 15 partially matching documents found.
Latest from PMHub
-
The heavy toll of COVID-19 on cancer patients
For example, all CAR-T cell therapies were paused as intensive care unit beds were needed to help COVID-19 patients recover. ... New therapies that minimize hospital visits may have to be prioritized by pharmaceuticals and MedTech companies.
-
Generating data on long-term outcomes with gene and other advanced therapies
Gene therapy and advanced cell-based therapies offer patients hope and the potential to make them ‘chronically well’. ... If you would like to discuss how we could help you deliver outcomes with your advanced therapies then please contact me:.
-
Precision medicine with precision management and precision pricing; ensuring affordability in the cell and gene therapy era
the cost curve to accommodate new and expensive cell and gene therapies. In addition to this, insurance plans demand lower co-pays for hospital costs i.e. ... can. Potential methods of payment proposed for expensive cell and gene therapies include:.
-
OPEN Health
Gavin Jones is looking forward to sessions on innovation in advanced therapies and working towards equitable access. ... Gene therapy and advanced cell-based therapies offer patients hope and the potential to make them ‘chronically well’.
-
Highlights in haematologic malignancy from ASH 2018
However, CAR T-cell therapies stop working in some patients and severe toxicity can also occur. ... Other abstracts reported on CAR T-cell therapies for multiple myeloma directed against the B-cell maturation antigen (BCMA).
More from PMHub
Approximately 0 fully matching, plus 15 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Medical Writer, Senior Medical Writer, Principal Medical Writer,...
-
Highly Competitive Salary, Bonus &Benefits
- Client Services Director – London or Home Based – Medical Commun...
-
Highly Competitive Salary, Bonus &Benefits
-
Senior Account Executive
-
Competitive Salary
-
Account Manager
-
Competitive Salary
- Freelance Medical Writer - Creative Healthcare Comms - 2 month t...
-
Excellent Day Rate
- Freelance Account Manager - Creative Healthcare Comms - Immediat...
-
Excellent Day Rate
- Senior Leadership Role – Medical Communications – North West
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account / Programme Manager - MedComms - Buckinghamshire
-
Highly Competitive Remuneration packages
-
Associate Account Director
-
Competitive Salary
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
-
Senior Medical Writer
-
Competitive Salary
- Senior Content Editor - Biotechnology
-
Salary TBC
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
-
Medical Editor
-
Competitive Salary
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
- CureVac outlines COVID-19 vaccine production plans ahead of regulatory approval
- Moderna’s booster vaccine for South African variant demonstrates promising early results
- GSK discontinues two feladilimab trials in head and neck cancer
- Novavax seeks FDA emergency approval for COVID-19 vaccine by May
- Merck & Co halts development of potential COVID-19 drug MK-7110
- Roche’s Ocrevus shows significant benefit in early-stage MS patients
- Roche reports strong diagnostics sales in Q1 as demand for COVID-19 tests continues
- EMA finds overall benefit-risk ‘remains positive’ for J&J COVID-19 vaccine
- Vertex to lead development of CRISPR Therapeutics-partnered gene therapy
- Health leaders welcome EDPB’s opinion on adequacy of UK’s data protection standards
- bluebird bio anticipates lift of clinical holds on LentiGlobin in mid-2021
- Havas Health & You appoints Pat Thistlethwaite as chief experience officer
Latest intelligence
- Empowering patients empowers results
- Patient-centricity is key when it comes to creating a more flexible, efficient and modern process for clinical trials...
- Don’t limit diversity to just representation in clinical trials
- What is the power of diversity in the healthcare environment? Can it make clinical trials more inclusive?...
- Oh no… not more training
- Paul Hutchings, founder of fox&cat, discusses ways to help your team manage pressure in a more human, pressure-centric and engaging way...
Quick links
Infographics
